Quoted Micro 24 April 2023

AQUIS STOCK EXCHANGE Valereum (VLRM) has sold Bitcoin mining assets to Aquis new entrant Vinanz (BTC) in return for 27.3 million shares at 3p each. This gives Valereum a 23.5% stake in Vinanz, which plans to become a Bitcoin mining company with facilities operated by third parties in the US and Canada. The company will […]

Quoted Micro 6 March 2023

AQUIS STOCK EXCHANGE Invinity Energy Systems (IES) is repaying the remaining $2.1m of its $2.5m convertible loan facility provided by RiverFort Global Opportunities out of the proceeds of the recent placing. There is a 10% redemption premium, making the total cost £1.92m. That stops dilution by the issue of six million shares. Related warrants can […]

Quoted Micro 24 October 2022

AQUIS STOCK EXCHANGE Chapel Down Group (CDGP) had a bumper grape crop in terms of quality and yield. Chapel Down has 750 acres of vines and the harvest was more than 2,000 tonnes, up from 1,400 tonnes last year, with a particularly good crop for sparkling wines. The English sparkling wine market grew by 29% […]

Andrew Hore – Quoted Micro 13 April 2020

AQUIS STOCK EXCHANGE Suffolk-based brewer Adnams (ADB) returned to profit in 2019. Revenues fell from £78.9m to £74.7m, while a loss of £877,000 was turned into a pre-tax profit of £39,000. Stripping out one-off costs, there was an underlying decline in profit. Investment in the brewery and a new IT system have led to some […]

Advanced Oncotherapy #AVO – Final Results statement plus CEO and Chairmans report

Advanced Oncotherapy (AIM: AVO), the developer of next generation proton therapy systems for cancer treatment, announces audited results for the year ended 31 December 2017, another year of significant technological development and installation of the Company’s first LIGHT system. Key highlights: ·     Successful integration of three of the four key LIGHT system structures significantly reducing technical […]

Radiation for Mesothelioma: Could Proton Therapy Be the Answer? – Advanced Oncotherapy #AVO

Researchers at the Maryland Proton Therapy Treatment Center say that a highly-targeted version of proton beam radiation could be the future of radiotherapy for malignant plural mesothelioma. Advanced Oncotherapy #AVO, is developing a unique, fully integrated, proton therapy system. The LIGHT System is expected to be the first commercially available linear proton accelerator for medical treatment […]

Advanced Oncotherapy #AVO – Update on Financing

Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that the Company has received £10 million from Yantai Cipu, through its affiliated entity Liquid Harmony, in relation to the balance of payments due under the Distribution Agreement announced on 7 December 2017. This completes the £30 million investment from […]

Advanced Oncotherapy #AVO – Successful testing supports the superior clinical outcomes of LIGHT

Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, provides the following technological update. The LIGHT system has been designed to electronically control the fast delivery of protons to the tumour site. This unique ability provides the opportunity to alter the exact amount of radiation that is given to every part of […]